Isoplasmal G

Valine, the active ingredient in Isoplasmal G, is an amino acid presented as an intravenous solution for parenteral use. It supports protein synthesis and metabolic functions in patients requiring nutritional support.\n\nGNH India supplies Isoplasmal G as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Isoplasmal G is used as a parenteral amino acid formulation to address nutritional and metabolic needs in clinical settings.\n\nParenteral nutrition: provides essential amino acids to support protein synthesis in patients unable to eat orally.\nHepatic support: supplies substrates such as ornithine and acetylcysteine that aid detoxification pathways in liver dysfunction.\nCatabolic states: delivers a balanced amino acid profile to mitigate muscle loss during severe illness or trauma.

Adverse reactions may occur with any intravenous amino acid solution. Monitoring during infusion is recommended.\n\nCommon Side Effects:\n- Mild infusion site erythema or pain\n- Transient nausea or vomiting\n- Slight increase in serum ammonia levels\n- Mild headache\n- Temporary elevation of liver enzymes\n\nSerious or Rare Side Effects:\n- Anaphylactic or severe hypersensitivity reaction\n- Acute renal impairment\n- Significant electrolyte disturbances\n- Severe metabolic acidosis\n- Thrombophlebitis at the infusion site

Isoplasmal G should be administered under medical supervision with appropriate monitoring.\n\nAssess renal and hepatic function before initiation: adjust infusion rate if impairment is present.\nMonitor serum electrolytes and ammonia during therapy: intervene if values deviate from normal range.\nAvoid concurrent administration of incompatible IV drugs: flush line between infusions.\nUse aseptic technique to prevent contamination: inspect solution for particulates before use.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify the safety or efficacy of Isoplasmal G.\n\nMajor Interactions (Avoid):\n- Concurrent use of high‑dose acetylcysteine with other sulfhydryl‑containing agents: risk of additive toxicity.\n- Co‑administration with nephrotoxic drugs (e.g., aminoglycosides): may exacerbate renal impairment.\n\nModerate Interactions (Monitor Closely):\n- Loop diuretics: may increase electrolyte loss, requiring closer monitoring.\n- Anticoagulants (e.g., heparin): amino acids can affect plasma protein binding, altering anticoagulant effect.\n- Other parenteral nutrition components: ensure compatible mixing to avoid precipitation.